This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for patients who received complete response or partial response after chemoradiotherapy. Finally consolidation therapy with dual immune checkpoint blockade (PD-1/CTLA-4) and thymosin alpha 1 was conducted for one year. The study aims to evaluate the efficacy and safety of this treatment regimen.
Males or females aged 18 to 75 years or older;
Patients must have histologically or cytologically confirmed small cell lung cancer (SCLC);
Stage II-III according to AJCC 8th staging system;
No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy;
Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
Mixed small cell and non-small cell lung cancer histology;
Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies;
Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;